

Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study

Running title: *Pastori, Menichelli & Lip et al.; Family history of atrial fibrillation and CVEs*

Daniele Pastori, MD, PhD^{1*}; Danilo Menichelli, MD^{1*}; Gregory Y.H. Lip, MD^{2*};

Angela Sciacqua, MD³; Francesco Violi, MD¹; Pasquale Pignatelli, MD, PhD¹;

ATHERO-AF study group

¹I Clinica Medica, Atherothrombosis Center, Department of Clinical, Internal Medicine, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy; ²Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; ³Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy

*contributed equally

Correspondence:

Dr. Daniele Pastori

I Clinica Medica, Atherothrombosis Center
Department of Clinical, Internal Medicine,
Anesthesiologic and Cardiovascular Sciences
Sapienza University of Rome
Viale del Policlinico 155
Roma, 00161 Italy
Tel: +390649970893
Fax +390649972309.
E-mail: daniele.pastori@uniroma1.it

Journal Subject Terms: Cardiovascular Disease; Myocardial Infarction; Mortality/Survival; Ischemic Stroke; Thrombosis

Abstract:

Background - To investigate the association between family history of atrial fibrillation (AF) with cardiovascular events (CVEs), major adverse cardiac events (MACE) and cardiovascular mortality.

Methods - Multicenter prospective observational cohort study including 1,722 non-valvular AF patients from February 2008 to August 2019 in Italy. Family history of AF was defined as the presence of AF in a first-degree relative: mother, father, sibling, or children. Primary outcome was a composite of CVEs including fatal/non-fatal ischemic stroke and myocardial infarction, and cardiovascular death. Second, we analyzed the association with MACE.

Results - Mean age was 74.6±9.4 years; 44% of women. Family history of AF was detected in 368 (21.4%) patients, and 3.5% had ≥2 relatives affected by AF. age of AF onset progressively decreased from patients without family history of AF, compared to those with single and multiple first-degree affected relatives (p<0.001). During a mean follow-up of 23.7 months (4,606 patients/years) 145 CVEs (3.15%/year), 98 MACE (2.13%/year) and 57 cardiovascular deaths (0.97%/year) occurred. After adjustment for cardiovascular risk factors, family history of AF was associated with a higher risk of CVEs (hazard ratio [HR] 1.524, 95% confidence interval [CI] 1.021-2.274, p=0.039) MACE (HR 1.917, 95% CI 1.207-3.045, p=0.006) and cardiovascular mortality (HR 2.008, 95% CI 1.047-3.851, p=0.036). Subgroup analysis showed that this association was modified by age, sex and prior ischemic heart disease.

Conclusions - In a cohort of elderly patients with a high atherosclerotic burden, family history of AF is evident in >20% of patients and was associated with an increased risk for CVEs and mortality.

Key words: mortality; atrial fibrillation; family history; cardiovascular events; new onset atrial fibrillation; familial atrial fibrillation

Nonstandard Abbreviations and Acronyms

AF: atrial fibrillation

ARIC: Atherosclerosis Risk in Communities

ATHERO-AF: Atherosclerosis in Atrial Fibrillation

CI: Confidence interval

CV: cardiovascular

CVEs: cardiovascular events

ESC: European society of cardiology

ESC/ACCF/AHA/WHF: European society of cardiology/American college of cardiology foundation/American heart association/ World heart federation

HR: hazard ratio

INR: international normalized ratio

IS: Ischemic stroke

MACE: major adverse cardiac events

MI: myocardial infarction

NOACs: non-vitamin K oral anticoagulants

TIA: transient ischemic attack

VKAs: vitamin K antagonists



Introduction

Patients with atrial fibrillation (AF) are at increased risk of cardiovascular and cerebrovascular ischemic complications¹⁻³ and mortality⁴. Several risk factors may predispose to new-onset AF⁵.⁶ Data from the Atherosclerosis Risk in Communities (ARIC) study showed that 56.5% of new-onset AF may be attributed to coexistent risk factors^{7,8}. They include modifiable risk factors, such as uncontrolled arterial hypertension, thyroid dysfunction, obesity, excessive alcohol consumption, sleep apnea syndrome and anticoagulation treatment⁹, and non-modifiable risk

factors including increasing age, congenital heart disease, severe valvulopathy, cardiac surgery and genetic predisposition^{7,8}. Concerning the latter aspect, genome wide association studies have identified several genetic susceptibility loci associated with AF¹⁰, including mutations in ion channels expressed in atria or ventricles possessing electrophysiological properties. Nevertheless, the translational value of these findings remains unclear, and genetic screening is not performed for all patients in everyday clinical practice¹¹.

Beyond complex genetic studies, family history of AF, as defined by the presence of AF in a first-degree relative, has been shown to confer an increased risk of early onset AF¹²⁻¹⁶. In a Danish population study, for example, the adjusted relative risk for incident AF was 3.37 [95% confidence interval (CI) 3.21–3.53] for the offspring from maternal probands, and 2.81 (95% CI 2.69–2.93) for offspring from paternal probands¹⁷. Furthermore, patients with persistent AF and a family history of AF had a higher recurrence after catheter ablation¹⁸. However, the association between family history of AF and clinical outcomes is more controversial, with studies reporting negative^{15,19} or positive²⁰ associations.

In this multicenter prospective observational cohort study, our aim was to investigate the prevalence of family history of AF, and second, to compare the incidence rate of cardiovascular events (CVEs), major adverse cardiac events (MACE) and cardiovascular mortality according to the presence of family history of AF.

Methods

Data and methods used in the analysis will be available for researchers upon reasonable request. We established a multicentre, prospective, observational cohort study, which included 1,722 AF Caucasian outpatients from the ATHERO-AF cohort at “Sapienza” University of Rome and from

“Magna Graecia” University of Catanzaro. The ATHERO-AF study started in February 2008 and is still ongoing (clinicaltrials.gov NCT01882114); for this analysis, follow-up was stopped at August 2019.

The study included patients with both Vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs). All patients were treated with oral anticoagulants, either VKAs (n=948) or NOACs (n=774). During the first clinical examination a completed personal medical history was collected, including drug therapy and comorbidities. The presence of AF was defined by resting 12-lead electrocardiogram; for patients with paroxysmal AF in sinus rhythm, a clinical documentation showing the presence of AF was collected. Patients were also asked about the age when AF was first diagnosed.



Exclusion criteria were prosthetic heart valves, or the presence of any severe valvulopathies, severe cognitive impairment, chronic infections (Human Immunodeficiency Virus infection, Hepatitis C virus, Hepatitis B virus) or systemic autoimmune diseases. Subjects were also excluded from the study if they had active cancer or liver insufficiency (eg, cirrhosis).

Definition of cardiovascular comorbidities

Definitions of cardiovascular risk factors have been previously reported²¹: Arterial hypertension: repeatedly elevated blood pressure ($\geq 140/\geq 90$ mmHg) or taking antihypertensive-drugs²².

Diabetes: a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l), or fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), or 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test or taking anti-diabetic drugs²³. Heart failure: presence of signs and symptoms typical of heart failure or reduced ejection fraction ($\leq 40\%$)²⁴.

All patients signed an informed written consent at study entry. The study was approved by the local ethic committee of “Sapienza” University and was conducted according to the declaration of Helsinki.

Results

Follow-up and definition of primary outcome

Follow-up was performed by periodic clinical evaluations or by telephone if patients missed 1 or more visit. For patients on VKAs, follow-up visit was scheduled at the anticoagulation clinic according their value of international normalized ratio (INR), and in any case, the longest period between two controls did not exceed 20 days. For patients on NOACs, patients after first prescription were visited at the outpatient clinic after 1, 3, 6 and 12 months according to ESC indications, and every 6-12 months afterwards.

Definition of clinical endpoints

Only the first event occurred during the follow-up was used for the analysis. Data of patients who were lost during follow-up were censored.

CVEs were defined as fatal/non-fatal ischemic stroke and myocardial infarction (MI), cardiac revascularization/coronary bypass surgery, cardiovascular death and transient ischemic attack (TIA). The diagnosis of MI was formulated according to the universal definition proposed by the Joint ESC/ACCF/AHA/WHF²⁵. If a patient died within 4 weeks of a stroke or heart attack, this event was recorded as fatal. Death was classified as cardiovascular unless a non-cardiovascular cause of death was identified. Cardiovascular death included sudden death, progressive heart failure, death related to surgical or percutaneous revascularization procedures. The diagnosis of ischemic stroke was determined by clinical manifestations then confirmed by



Circulation: Arrhythmia and Electrophysiology

radiological findings. The TIA was defined according to the Classification of cerebrovascular disease III²⁶. Only the first event was used for the analysis, and confirmation of the primary event was made by a blinded commission that did not participate in patient recruitment and was not aware of the characteristics of any of the enrolled patients. We also analyzed the occurrence of MACE, which consisted of fatal-nonfatal MI, cardiac revascularization and cardiovascular death (excluding fatal and non-fatal stroke and TIA).

Validation of endpoints

Data on CVEs, MACE and CV death were prospectively collected during follow-up. When an event occurred, a standardized form was filled in by the investigators. Details on each event were registered, as well as death certificates, hospital discharge letter or copy of the medical records of hospitalization, and other clinical documentation (i.e. radiology and laboratory data) were also obtained from patients, or in case of death, from relatives of patients or from general practitioner. Adjudication of cardiovascular events was performed by a committee composed by physicians who did not participate to the recruitment of patients and was unaware of the clinical and laboratory characteristics of any enrolled patient. Each member of the committee independently evaluated and adjudicated events in a blinded manner. In case of discordant evaluation or difficult adjudication of an event, the committee decided to award the event in a collegial way.

Definition of family history of AF

Family history of AF was defined as the presence of AF in at least one first-degree relative among mother, father, siblings or children. Multiple family history of AF was defined as the presence of AF in 2 or more relatives. These data were recorded during the first visit by a trained physician by direct face-to-face interview with patient and relatives when available. Patients were asked if they knew about cases of AF in the first-degree relatives, and relatives were also

interviewed. In addition, as confirmation, they were also asked if someone of the relatives was taking anticoagulant drugs. Patients who were not sure about these questions were excluded.

Relatives of patients have not been included in the study cohort.

Statistical analysis

Categorical variables were reported as a number or percentage and compared by the Pearson's χ^2 test. Continuous variables were expressed as mean \pm standard deviation and Student t-test was used to compare means. We divided the cohort into 2 groups based on the presence/absence of family history of AF and we performed a descriptive analysis of groups characteristics. Annual incidence rates of each endpoint were calculated. Multivariable proportional hazard Cox regression analysis was used to estimate the relative hazard ratio (HR) with 95% confidence interval (95% CI) for each variable. The following variables were entered as covariates in the multivariable model: age >75 years, age of AF onset (years), persistent/permanent AF (vs. paroxysmal), women, arterial hypertension, diabetes mellitus, previous cerebrovascular events, heart failure, and previous ischaemic heart disease.

We built three separate survival models for: (i) CVEs; (ii) MACE (excluding thromboembolic events); and (iii) cardiovascular deaths. Adjusted survival curves were displayed according to the presence of family history of AF. Subgroup analysis by sex, age > 70 or ≤ 70 years, and prior cardiovascular disease was also performed.

Only p-values below 0.05 were considered statistically significant. All the tests used are two-sided and the analyses were performed using electronic software packages (SPSS-25.0, SPSS Inc., IBM Corp., Armonk, NY, USA; license provided by Sapienza University of Rome).

Results

Patient characteristics according to study groups are summarised in Table 1. We included 1,722 anticoagulated AF patients (mean age 74.6 ± 9.4 years; 44% female). In the cohort there was a high prevalence of atherosclerotic risk factors, with a high prevalence of arterial hypertension (87.2%), diabetes mellitus (21.7%), and previous cardiovascular and cerebrovascular ischemic events (17.3% and 14.5%) (Table 1).

A family history of AF was detected in 368 (21.4%) patients. Of these, 3.5% had more than one first-degree family member with AF (Figure 1, Panel A). The relatives that were most frequently affected by AF were siblings (51.9%), followed by parents (32.3% and 21.2%, mother and father respectively) and children (6.8%), as shown in Figure 1, Panel B.



Patients with family history of AF were younger than those without but no other significant difference regarding cardiovascular risk factors was found (Table 1). Of note, the age of onset of AF progressively decreased from patients without familial history, to those with single and multiple first-degree relatives affected, as shown in Figure 2 ($p < 0.001$).

Survival analysis

Cardiovascular events

During a mean follow-up of 23.7 months (yielding 4,606 patients/years) 145 CVEs occurred (3.15%/year) and 39 patients were lost and other 14 were censored because newly diagnosed with cancer. On multivariable Cox regression analysis (Table 2), family history of AF was an independent predictor for CVEs, after adjustment for traditional cardiovascular risk factors.

Further independent risk factors for CVEs were age ≥ 75 years, heart failure, previous ischaemic heart disease, previous IS/TIA and age of AF onset (Table 2). Figure 3, Panel A shows the adjusted survival probability free from CVEs of patients with and without family history of AF.

Major adverse cardiovascular events (MACE)

The MACE endpoint (excluding thromboembolic events) occurred in 98 patients (2.13%/year). On multivariable Cox proportional regression analysis, we found that the family history of AF was independently associated with MACE occurrence (Table 2). Other risk factors for MACE were the presence at baseline of heart failure, a history of ischemic heart disease and the age of onset of AF (Table 2). Figure 3, Panel B shows the adjusted survival probability free from MACE of patients with and without family history of AF.

Cardiovascular death

In our cohort, 57 cardiovascular deaths occurred (0.97%/year). On multivariable Cox survival analysis (Table 2) family history of AF was an independent predictive risk factor for cardiovascular death, together with age of onset of AF, heart failure and previous ischaemic heart disease. Figure 3, Panel C shows the adjusted survival probability free from cardiovascular death of patients with and without family history of AF.

Subgroup analysis

Similar results were obtained using age as continuous variable for all the three endpoints considered (Supplementary table 1).

A subgroup analysis according to age, showed that the association between family history of AF and risk of CVEs, MACE and CV death was evident in patients aged >70 years but not in those \leq 70 years (Table 3). When we divided patients according to prevalent cardiovascular disease, we found that the association between family history of AF and risk of CVEs, MACE and CV death was evident only in patients with prior coronary artery disease. Finally, the analysis by sex, showed a significant association between family history of AF with MACE and CV death in women but not in men (Table 3).



Circulation, Arrhythmia and Electrophysiology

Family history for cardiovascular disease

We found that 577 (33.5%) patients had a family history for cardiovascular disease, including cardiovascular and cerebrovascular disease. Family history for cardiovascular disease was not associated with CVEs during follow-up (HR 0.97, 95% CI 0.67-1.40).

Discussion

In this multicenter prospective observational cohort study, our principal finding was that more than 20% of patients with AF have a first-degree relative suffering from the same arrhythmia. Second, the presence of family history of AF was associated with an increased risk of CVEs, MACE and cardiovascular mortality.



The data from our work agree with the previous studies that also reported that the presence of family history of AF was a risk factor for early new-onset AF compared with patients without a family history of AF^{12, 27, 28}. We also found that when ≥ 2 first-degree relatives had AF, the age of onset of AF was even lower than patients with only one affected family member (62 vs. 67 years, respectively).

In the present study, which included Caucasian elderly AF patients with multiple atherosclerotic risk factors, family history of AF was associated with an increased risk of ischemic complications, such as CVEs, MACE and cardiovascular mortality.

Our findings are partially in contrast with previous studies on this subject. For example, a Danish retrospective study showed no difference in mortality and thromboembolic risk in patients with and without family history of AF¹⁹. However, some important differences between our study and the Danish cohort may potentially account for this difference. For instance, the mean age of the Danish patients was 50 years, compared to 75 years in the present study;

moreover, only 20% of that study were female, and there was a very low prevalence of cardiovascular risk factors compared to our cohort (eg. hypertension 27.1% vs 87.2% and diabetes 3.8% vs. 21.7%, respectively)¹⁹. A more recent large study from Taiwan included 244,067 patients with AF, and also showed no association between family history of AF and risk of MACE¹⁵. Even in this study, the majority of patients were relatively young (82.1% were aged <65 years), only 13.6% of female, and 34.5% were hypertensive¹⁵.

What should also be taken into consideration is that all patients in our study were anticoagulated, whilst in both of the two studies mentioned above, there was a very low proportion of patients was on treatment with oral anticoagulants: for example, <30% in the Danish cohort¹⁹ and <3% in the Taiwan study¹⁵. This may have affected the rate of cardiovascular events registered in the studies. Finally, one large Canadian study showed that the incidence rates for stroke/TIA were higher in offspring with a parental history of AF than those without (195.0 vs. 156.6 per 100 000 person-years)²⁰. Also, parental AF was also associated with elevated risk in offspring of stroke/TIA (HR 1.11; 95% CI, 1.04–1.18) or AF (HR 1.75; 95% CI, 1.55–1.97)²⁰.

Our study has clinical implications. The significantly lower age of onset of AF in patients with single and multiple family history of AF implies that subjects with a first-degree suffering from AF should be advised to perform screening and clinical evaluation to detect new-onset AF. This may lead to a potential saving of health-related costs related to AF complications²⁹. The age of onset of AF in our study, likely representing the length of the disease since AF was first diagnosed, was independently associated with the ischemic risk, again reinforcing the need for early screening of relatives of patients affected by AF.



Circulation: Arrhythmia and Electrophysiology

Furthermore, the significant association between family history of AF and outcomes may represent a new risk factor which may easily be obtained by an accurate interview of the patient during the first visit. This information may turn particularly useful in some subgroups of patients, such as those in whom the choice whether to start or not an oral anticoagulation treatment is uncertain. Thus, the presence of a family history of AF, especially if multiple, may help physician in the decision-making process.

Subgroup analysis showed that the association between family history of AF and cardiovascular outcomes is strongly modified by sex, age and prevalent cardiovascular disease, underlying that there is complex interaction between polygenic factors, demographic characteristics and environmental variables. In particular, we did not find a significant difference in the proportion of women between the two groups of patients with and without family history of AF, which is in contrast with a previous study on 5,884 AF patients from the Health eHeart Study³⁰. Female sex was not associated with cardiovascular outcomes in our study, differently from findings from the RACE II trial in which female sex was associated with the composite of CVEs but not with increased cardiovascular death³¹. Of interest, the association between family history and outcomes was stronger in women than men, suggesting a sex-based difference. Further study on the relationship between family history of AF and sex are needed.

The mechanisms underlying our results may be several. The similar baseline cardio-metabolic characteristics of patients with and without family history of AF suggest that other variables than the traditional cardiovascular risk factors may confer an increased risk of both early onset of AF and of cardiovascular events in these patients. These aspects may pertain structural and electrophysiology characteristics, as suggested by documented genetic-based alterations in some proteins like myosin³² or ion channels³³. It would be therefore interesting to

study heart structure and function as well as electrical conduction in patients with family history of AF. Genome sequencing of patients with family history may also provide novel insights on this topic and may help to better characterize risk profile of these patients³⁴.

The burden of family history seems also to influence the risk of AF, as shown by individuals with ≥ 1 affected parent and ≥ 1 affected sibling in whom the odds ratio for having new AF was 5.56 (95% CI 4.99 to 6.20). This is in keeping with our study in which patients with multiple relatives affected by AF have a lower age of onset of AF compared to those with only 1 or none affected relative³⁵.

Limitations

Our study has limitations. First, this is an observational study, and it is not possible to establish a cause-effect relationship between the presence of family history of AF and the onset of ischemic complications. Second, the presence of family history of AF was recorded through a direct face-to-face interview with the patient and with relatives (when available), and although performed by dedicated staff, may still present inaccuracies in recording of familial disorders. However, when patients or relatives were not sure about the type of cardiac disorder, these were excluded.

Furthermore, we cannot exclude that other factors/diseases may contribute to the onset of AF in relatives of patients. Third, our data comes from a cohort of all Caucasian elderly patients, thus the prevalence and impact on outcomes cannot be applied to populations of other ethnic groups. Fourth, the cohort was composed by patients enrolled in a hospital-based anticoagulation clinic. Finally, we did not investigate differences in the association between single or multiple family history of AF links and ischemic complications, due to the limited number of patients with multiple family history. Similarly, larger studies are needed to analyse the relationship between

different type of family history of AF (i.e. mother or father) and CVEs. Results may also be different in AF patients treated with other antithrombotic drugs.

Conclusion

In a cohort of elderly patients with a high atherosclerotic burden, family history of AF is evident in >20% of patients and was associated with an increased risk for CVEs and mortality. First-degree relatives of patients with AF should undergo screening and clinical evaluation to detect new-onset AF and appropriate cardiovascular prevention strategies.

Sources of Funding: none

Appendix: ATHERO-AF study group members: Mirella Saliola, Marco Antonio Casciaro, MD, Greta Rende, MD, Tommasa Vicario, MD, Francesco Del Sole, MD, Tommaso Bucci, MD.

Disclosures: none.

References:

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2014;64:e1-76.
2. Pastori D, Pignatelli P, Farcomeni A, Nocella C, Bartimoccia S, Carnevale R, Violi F. Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. *Oncotarget.* 2016;7:39143-39147.
3. Pastori D, Pignatelli P, Angelico F, Farcomeni A, Del Ben M, Vicario T, Bucci T, Raparelli V, Cangemi R, Tanzilli G, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. *Chest.* 2015;147:1644-1650.
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol.* 1998;82:2N-9N.

5. Li Y, Pastori D, Guo Y, Wang Y, Lip GYH. Risk factors for new-onset atrial fibrillation: A focus on Asian populations. *Int J Cardiol.* 2018;261:92-98.
6. Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, Perel P, Morley K, Banerjee A, Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. *Thromb Haemost.* 2017;117:837-850.
7. Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse HF, et al. Atrial fibrillation. *Nat Rev Dis Primers.* 2016;2:16016.
8. Kwon Y, Norby FL, Jensen PN, Agarwal SK, Soliman EZ, Lip GY, Longstreth WT, Jr., Alonso A, Heckbert SR, Chen LY. Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). *PLoS One.* 2016;11:e0147065.
9. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. *Thromb Haemost.* 2013;110:1189-1198.
10. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-Nurasyid M, Krijthe BP, Lubitz SA, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet.* 2012;44:670-675.
11. Hucker WJ, Hanley A, Ellinor PT. Improving Atrial Fibrillation Therapy: Is There a Gene for That? *J Am Coll Cardiol.* 2017;69:2088-2095.
12. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, Villalon ML, Vasan RS, Pencina MJ, Levy D, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. *JAMA.* 2010;304:2263-2269.
13. Gundlund A, Olesen JB, Peterson ED, Gislason GH, Fosbol EL. Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. *J Comp Eff Res.* 2017;6:257-263.
14. Zoller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. *J Am Heart Assoc.* 2012;2:e003384.
15. Chang SH, Kuo CF, Chou IJ, See LC, Yu KH, Luo SF, Huang LH, Zhang W, Doherty M, Wen MS, et al. Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study. *JAMA Cardiol.* 2017;2:863-870.

16. Alzahrani Z, Ornelas-Loredo A, Darbar SD, Farooqui A, Mol D, Chalazan B, Villagrana NE, McCauley M, Lazar S, Wissner E, et al. Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. *JAMA Netw Open*. 2018;1:e182497.
17. Gundlund A, Christiansen MN, Hansen ML, Olesen JB, Zahir D, Kober L, Gislason GH, Piccini JP, Peterson ED, Torp-Pedersen C, et al. Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark. *Europace*. 2016;18:658-664.
18. Kapur S, Kumar S, John RM, Stevenson WG, Tedrow UB, Koplan BA, Epstein LM, MacRae CA, Michaud GF. Family history of atrial fibrillation as a predictor of atrial substrate and arrhythmia recurrence in patients undergoing atrial fibrillation catheter ablation. *Europace*. 2018;20:921-928.
19. Gundlund A, Olesen JB, Staerk L, Lee C, Piccini JP, Peterson ED, Kober L, Torp-Pedersen C, Gislason GH, Fosbol EL. Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. *J Am Heart Assoc*. 2016;5.
20. McAlister FA, Yan L, Roos LL, Lix LM. Parental Atrial Fibrillation and Stroke or Atrial Fibrillation in Young Adults. *Stroke*. 2019;50:2322-2328.
21. Pastori D, Nocella C, Farcomeni A, Bartimoccia S, Santulli M, Vasaturo F, Carnevale R, Menichelli D, Violi F, Pignatelli P, et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2017;70:1455-1462.
22. Mancia G, Fagard R, Narkiewicz K, Redan J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens*. 2013;31:1925-1938.
23. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013;34:3035-3087.
24. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2012;14:803-869.



25. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Katus HA, Lindahl B, Morrow DA, et al. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020-35.
26. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke*. 1990;21:637-676.
27. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. *Hum Genet*. 2005;118:179-184.
28. Fox CS, Parise H, D'Agostino RB, Sr., Lloyd-Jones DM, Vasani RS, Wang TJ, Levy D, Wolf PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. *JAMA*. 2004;291:2851-2855.
29. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. *Am J Med*. 2019;132:856-861.
30. Fan SM, Fann A, Nah G, Pletcher MJ, Olgin JE, Marcus GM. Characteristics of Atrial Fibrillation Patients with a Family History of Atrial Fibrillation. *J Atr Fibrillation*. 2019;12:2198.
31. Kloosterman M, Crijns H, Mulder BA, Groenveld HF, Van Veldhuisen DJ, Rienstra M, Van Gelder IC. Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. *Europace*. 2019.
32. Orr N, Arnaout R, Gula LJ, Spears DA, Leong-Sit P, Li Q, Tarhuni W, Reischauer S, Chauhan VS, Borkovich M, et al. A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. *Nat Commun*. 2016;7:11303.
33. Bartos DC, Anderson JB, Bastiaenen R, Johnson JN, Gollob MH, Tester DJ, Burgess DE, Homfray T, Behr ER, Ackerman MJ, et al. A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. *J Cardiovasc Electrophysiol*. 2013;24:562-569.
34. Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh BJ, Shen WK, Hammill SC, Packer DL, Olson TM. Familial atrial fibrillation is a genetically heterogeneous disorder. *J Am Coll Cardiol*. 2003;41:2185-2192.
35. Berntsson J, Li X, Zoller B, Martinsson A, Andell P, Lubitz SA, Engstrom G, Sundquist K, Smith JG. Risk of Stroke in Patients With Atrial Fibrillation Is Associated With Stroke in Siblings: A Nationwide Study. *J Am Heart Assoc*. 2020;9:e014132.

Table 1. Characteristics of the study population according to the presence of familial atrial fibrillation.

	Total (n=1,722)	Patients without family history AF (n= 1,354)	Patients with family history AF (n= 368)	p-value
Age (years)	74.6±9.4	75.2±9.22	72.3±9.73	<0.001*
Age >75 years (%)	52.2	54.2	44.8	0.001 [†]
Age of AF onset (years)	69.9±11.6	70.8±11.6	66.3±10.88	<0.001 [†]
Persistent/permanent AF (%)	56.4	57.3	53.4	0.192 [†]
Women (%)	49.9	49.2	52.9	0.217 [†]
NOAC (vs VKAs)	44.9	44.5	46.7	0.443 [†]
Arterial hypertension (%)	87.2	87.4	86.6	0.724 [†]
Diabetes mellitus (%)	21.7	22.1	19.9	0.391 [†]
Previous cerebrovascular events (%)	14.5	14.8	13.4	0.558 [†]
Heart failure (%)	16.3	16.8	14.4	0.297 [†]
Previous ischaemic heart disease (%)	17.3	17.2	17.6	0.876 [†]
CHA ₂ DS ₂ VASC score	3.5±1.5	3.54±1.48	3.35±1.54	0.026 [#]

AF: atrial fibrillation, NOAC: non-vitamin K anticoagulants, VKA: vitamin K antagonist

* student t test; [†] χ^2 test



Circulation: Arrhythmia and Electrophysiology

Table 2. Multiple Cox regression analysis of risk factors for cardiovascular events (Panel A), major adverse cardiovascular events (Panel B), and cardiovascular death (Panel C).

Panel A. CVEs	Hazard Ratio	95% Confidence Interval		p-value
		Lower	Upper	
Age \geq 75 years	1.60	1.02	2.50	0.042
Persistent/permanent AF	0.88	0.62	1.23	0.442
Age of AF onset	1.04	1.02	1.07	0.002
Female	0.78	0.55	1.10	0.159
Arterial hypertension	1.12	0.58	2.15	0.733
Diabetes mellitus	1.24	0.85	1.79	0.265
Heart failure	1.90	1.30	2.78	0.001
Previous cerebrovascular events	1.98	1.35	2.88	<0.001
Previous ischaemic heart disease	1.73	1.20	2.49	0.003
Family history of AF	1.52	1.02	2.27	0.039
Panel B. MACE (excluding thromboembolism)	Hazard Ratio	95% Confidence Interval		p-value
		Lower	Upper	
Age \geq 75 years	1.32	0.76	2.28	0.321
Persistent/permanent AF	1.00	0.66	1.52	0.996
Age of AF onset	1.05	1.02	1.08	0.002
Female	0.80	0.52	1.21	0.287
Arterial hypertension	1.30	0.57	3.00	0.535
Diabetes mellitus	1.16	0.74	1.83	0.521
Heart failure	2.18	1.40	3.41	0.001
Previous cerebrovascular events	1.47	0.90	2.40	0.126
Previous ischaemic heart disease	1.98	1.28	3.06	0.002
Family history of AF	1.92	1.21	3.05	0.006
Panel C. Cardiovascular death	Hazard Ratio	95% Confidence Interval		p-value
		Lower	Upper	
Age \geq 75 years	1.65	0.73	3.72	0.227
Persistent/permanent AF	1.32	0.74	2.37	0.348
Age of AF onset	1.10	1.05	1.15	<0.001
Female	0.72	0.42	1.26	0.253
Arterial hypertension	4.21	0.58	30.58	0.155
Diabetes mellitus	1.39	0.77	2.50	0.275
Heart failure	2.18	1.22	3.90	0.008
Previous cerebrovascular events	1.65	0.90	3.04	0.106
Previous ischaemic heart disease	1.81	1.02	3.21	0.044
Family history of AF	2.01	1.05	3.85	0.036

AF: atrial fibrillation; CVEs: cardiovascular events; MACE: major adverse cardiac events

Table 3. Adjusted hazard ratio (95% confidence interval) for family history of AF according to specific subgroups of patients.

	Cardiovascular events	Major adverse cardiac events	Cardiovascular death
Age > 70 years	1.58 (1.00-2.50)	1.83 (1.07-3.14)	2.15 (1.06-4.37)
Age ≤ 70 years	1.24 (0.55-2.81)	2.20 (0.85-5.70)	1.16 (0.21-6.46)
Men	1.39 (0.80-2.41)	1.46 (0.80-2.80)	1.72 (0.71-4.18)
Women	1.74 (0.95-3.17)	3.04 (1.52-6.11)	2.69 (1.01-7.22)
Prior cardiovascular disease	2.11 (1.15-3.88)	2.85 (1.44-5.65)	3.06 (1.21-7.77)
No prior cardiovascular disease	1.22 (0.70-2.10)	1.36 (0.70-2.62)	1.26 (0.47-3.37)

Covariates were the same used in table 2 (excluding the variable used to categorize results).



Figures Legends:

Figure 1. Panel A. Prevalence of single and multiple familiarity for atrial fibrillation (AF) in first degree relatives in the whole cohort. Panel B. Prevalence of different types of familiarity.

Figure 2. Age of onset of atrial fibrillation (AF) in patients without and in those with single and multiple family history of AF.

Figure 3. Adjusted Cox survival curves in patients with and without family history of AF for cardiovascular events (Panel A), major adverse cardiovascular events (MACE, Panel B) and cardiovascular death (Panel C).

What Is Known?


- Patients with a first-degree relative affected by atrial fibrillation (AF) are at increased risk of developing this arrhythmia.
- The association between family history and ischemic complications in AF is still controversial.

What the Study Adds?


- Patients with AF and a family history have an earlier onset of AF compared to patients without
- Family history of AF is associated with an increased risk for cardiovascular events and mortality.




Circulation: Arrhythmia and Electrophysiology




Circulation: Arrhythmia and Electrophysiology





A



Circulation: Arrhythmia and Electrophysiology


Number at risk

Group: 0

1338 755 367 194 81 43 26 20


Group: 1

367 207 99 45 25 12 9 8

B

American Heart Association.

C



Circulation: Arrhythmia and Electrophysiology

1,722 patients with atrial fibrillation taking oral anticoagulants

Anticoagulation Clinic



 **23.7 months of follow up**

Family history of AF in a first-degree relative was detected in 21.4% of patients



Family history of AF associated with:

- ✓ **Early onset of AF**
- ✓ **Increased risk of cardiovascular events, MACE and mortality**

